The treatment of patients with non-small cell lung cancer carrying uncommon EGFR mutations, HER2 mutations, or brain metastases: a systematic review of pre-clinical and clinical findings for dacomitinib

BACKGROUND: Accumulating evidence has shown that dacomitinib has potential activities for patients with non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, human epidermal growth factor receptor 2 (HER2) mutations, or central nervous system (CNS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Li-Li, Luo, Xiao-Zhen, Xie, Ling-Ling, Lei, Xiao-Zhen, Zhu, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493789/
https://www.ncbi.nlm.nih.gov/pubmed/37701115
http://dx.doi.org/10.21037/tcr-23-95

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493789/
https://www.ncbi.nlm.nih.gov/pubmed/37701115
http://dx.doi.org/10.21037/tcr-23-95

Ejemplares similares